查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953466

皮膚毒性測試市場－全球產業規模、佔有率、趨勢、機會與預測：測試類型、測試方法類型、最終用戶、地區和競爭格局，2021-2031年

Dermal Toxicity Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Testing Method Type (In Vivo Testing, and In Vitro Testing ), By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球皮膚毒性​​測試市場預計將從 2025 年的 21.1 億美元成長到 2031 年的 33.8 億美元，複合年成長率為 8.17%。

這個測試領域對於評估潛在的皮膚損傷（例如刺激和腐蝕）以及局部接觸引起的全身性影響至關重要，是製藥、化學和化妝品行業安全合規的基礎。該市場的成長主要得益於嚴格的監管要求（例如 REACH 法規）以及日益成長的倫理努力，即以體外（試管內）和電腦模擬等替代方法取代動物試驗。例如，歐洲化學工業理事會 (Cefic) 報告稱，到 2024 年，歐洲化學工業的銷售額將達到 6,350 億歐元，這足以說明需要評估的物質規模之大。

市場概覽
預測期 2027-2031
市場規模：2025年 21.1億美元
市場規模：2031年 33.8億美元
複合年成長率：2026-2031年 8.17%
成長最快的細分市場 體外試驗
最大的市場 北美洲

儘管存在這些成長要素，但市場在監管協調和替代調查方法的科學檢驗方面仍面臨許多重大障礙。雖然非動物模型已取得進展，但要證明其與複雜的生物系統完全等效仍然是一項重大挑戰。這項挑戰可能會阻礙這些調查方法的普遍接受，並限制市場的進一步擴張，因為證明其與傳統模型具有可比性仍然是一個重大障礙。

市場促進因素

全球化妝品和個人護理行業的強勁成長，得益於複雜配方和新成分的不斷湧現，而這些都需要進行全面的安全評估，這也成為皮膚毒性測試市場的主要驅動力。隨著消費者對產品安全性的關注度日益提高，製造商必須進行廣泛的皮膚相容性評估，以確保符合國際標準並預防不良反應。這種高強度的產品開發週期催生了對毒性評估的巨大需求，以確保產品已做好上市準備。歐洲化妝品協會（Cosmetics Europe）發布的《2024年年度報告》顯示，預計到2024年，歐洲化妝品和個人保健部門的零售額將達到1040億歐元，這充分體現了這一需求的規模。

同時，受倫理考量和監管變革（例如FDA現代化法案2.0）的推動，市場正經歷變革，非動物實驗替代方法正被迅速採用。這一轉變加速了3D重建人類表皮模型的商業化進程，與動物實驗相比，這些模型在預測人類皮膚反應方面具有更高的準確性。賽多利斯公司於2025年4月達成協議，以8,000萬美元收購3D組織模型領域的領導企業MatTek，凸顯了這些創新技術的戰略重要性。此外，對專業外部專家的依賴也為合約研究領域提供了支持，查爾斯河實驗室2025年11月公佈的「藥物發現與安全性評估」業務收入達6.007億美元便印證了這一點。

市場挑戰

全球皮膚毒性​​測試市場面臨的主要障礙之一是替代測試方法的科學檢驗和監管協調過程的複雜性。要證明非動物模型（例如In Silico和體外技術）能夠完全模擬完整生物系統的複雜生理反應，在科學上極具挑戰性，這往往導致監管機構在核准這些新方法時猶豫不決。這種謹慎態度造成了法規環境的碎片化，特定測試方法的核准情況於特定地區，這給面臨各種合規標準的服務提供者和客戶帶來了極大的不確定性。

因此，缺乏統一標準減緩了先進替代技術的商業性化應用，並限制了市場的獲利潛力。製造商面臨更高的合規成本和產品上市延遲，這實際上阻礙了該行業逐步淘汰傳統動物試驗的計劃。其經濟影響巨大。根據歐洲化妝品協會（Cosmetics Europe）的報告顯示，預計到2024年，歐洲化妝品和個人護理市場的零售額將達到1040億歐元，但由於缺乏普遍認可的、簡化的檢驗通訊協定來評估如此龐大的產品量，直接阻礙了市場的營運效率和成長軌跡。

市場趨勢

將人工智慧 (AI) 應用於預測毒理學正在改變市場格局，使安全性評估從被動的動物試驗觀察轉向數據驅動的預測方法。這一趨勢利用機器學習演算法快速分析龐大的化合物庫並預測毒性終點，從而鼓勵製藥公司利用這些平台來降低早期資產的風險。 Exscientia 的案例凸顯了計算毒理學的商業性可行性。該公司在 2024 年 10 月的新聞稿中（與其和賽諾菲的合作相關）宣布，其人工智慧驅動的平台已接受1500 萬美元的里程碑付款，用於識別符合複雜要求的先導化合物。

同時，皮膚組織晶片平台的商業化進程正在推進，從學術原型發展成為工業化、可擴展的系統。這些微生理裝置能夠模擬人體皮膚的動態微環境，並因其在評估藥物吸收和全身毒性方面的卓越能力，正逐漸成為靜態細胞培養的替代方案。目前，各方正投入大量資金以擴大這些技術的生產能力。例如，2024年4月，CN Bio宣布完成2,100萬美元的B輪資金籌措，以加速其PhysioMimix系統的商業性化規模化生產，這印證了業界對生理相關毒理學模型的強勁需求。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球皮膚毒性​​測試市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依測試類型（皮膚刺激性測試、皮膚致敏性測試）
    • 依試驗方法（體內試驗（動物試驗）和體外試驗（基於細胞或組織的試驗））
    • 按最終用戶分類（製藥業、化妝品和個人保健產品行業、化學工業、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美皮膚毒性測試市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲皮膚毒性測試市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區皮膚毒性測試市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲皮膚毒性測試市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲皮膚毒性測試市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球皮膚毒性​​測試市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • SGS SA
  • Covance, Inc
  • Bio-Rad Laboratories Inc.
  • Qiagen NV
  • GE Healthcare
  • Eurofins Scientific Inc
  • Merck KgaA
  • Thermo Fisher Scientific, Inc.
  • Charles River Laboratories International, Inc.
  • Catalent, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17199

The Global Dermal Toxicity Testing Market is projected to increase from USD 2.11 Billion in 2025 to USD 3.38 Billion by 2031, expanding at a CAGR of 8.17%. This testing sector is essential for evaluating potential skin damage, such as irritation or corrosion, as well as systemic effects resulting from topical exposure, serving as a cornerstone for safety and compliance within the pharmaceutical, chemical, and cosmetic industries. Growth in this market is largely fueled by strict regulatory mandates like REACH and a rising ethical commitment to substitute animal testing with in vitro and in silico alternatives. Highlighting the scale of substances requiring evaluation, the European Chemical Industry Council (Cefic) reported that the European chemical industry achieved a turnover of €635 billion in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.11 Billion
Market Size 2031USD 3.38 Billion
CAGR 2026-20318.17%
Fastest Growing SegmentIn Vitro Testing
Largest MarketNorth America

Despite these growth factors, the market encounters significant obstacles related to the regulatory harmonization and scientific validation of alternative testing methodologies. While non-animal models are progressing, proving their complete equivalence to complex biological systems remains a major difficulty. This challenge potentially hinders the universal acceptance of these methods and restricts the broader expansion of the market, as demonstrating comparable efficacy to traditional models continues to be a substantial hurdle.

Market Driver

The robust growth of the global cosmetics and personal care industry acts as a major catalyst for the dermal toxicity testing market, spurred by the constant release of complex formulations and new ingredients necessitating thorough safety reviews. As consumers become increasingly vigilant about product safety, manufacturers must perform extensive dermal compatibility assessments to ensure compliance with international standards and prevent adverse reactions. This intense product development cycle drives a high demand for toxicological evaluations to ensure market readiness, a scale illustrated by Cosmetics Europe's 'Annual Report 2024', which noted that the European cosmetics and personal care sector achieved retail sales of €104 billion in 2024.

Concurrently, the market is transforming due to the swift uptake of alternative non-animal testing methods, driven by ethical considerations and regulatory updates like the FDA Modernization Act 2.0. This transition has hastened the commercialization of 3D reconstructed human epidermis models, which provide superior predictive accuracy for human skin reactions compared to animal testing. The strategic importance of these innovations is highlighted by Sartorius's agreement in April 2025 to acquire MatTek, a leader in 3D tissue models, for $80 million. Furthermore, the reliance on specialized external expertise supports the contract research sector, evidenced by Charles River Laboratories reporting $600.7 million in revenue for its Discovery and Safety Assessment segment in November 2025.

Market Challenge

A significant barrier facing the Global Dermal Toxicity Testing Market is the complex process of scientifically validating and harmonizing regulations for alternative testing methods. Establishing that non-animal models, such as in silico and in vitro techniques, can fully mimic the intricate physiological responses of complete biological systems is scientifically challenging, causing regulatory bodies to often hesitate in endorsing these new approaches. This caution creates a fragmented regulatory environment where specific tests may be approved in one region but not another, generating considerable uncertainty for service providers and clients navigating diverse compliance standards.

As a result, the absence of harmonization slows the commercial uptake of advanced alternative technologies and limits the market's revenue potential. Manufacturers encounter higher compliance costs and delayed product launches, which effectively stalls the industry's intended shift away from traditional animal-based testing. The economic implications are significant; Cosmetics Europe reported €104 billion in retail sales for the European cosmetics and personal care market in 2024, yet the lack of universally accepted, streamlined validation protocols for assessing this vast volume of products directly impedes the market's operational efficiency and growth trajectory.

Market Trends

The integration of Artificial Intelligence into Predictive Toxicology is transforming the market by shifting safety assessments from reactive, animal-based observations to proactive, data-centric predictions. This trend involves the use of machine learning algorithms to rapidly analyze extensive chemical libraries and forecast toxicity endpoints, encouraging pharmaceutical companies to utilize these platforms for de-risking early-stage assets. The commercial viability of computational toxicology is exemplified by Exscientia, which, according to an October 2024 press release regarding its collaboration with Sanofi, received $15 million in milestone payments after its AI-driven platform successfully identified lead compounds meeting complex requirements.

Simultaneously, the commercialization of Dermal Organ-on-a-Chip platforms is advancing the sector by evolving from academic prototypes to scalable, industrially robust systems. These microphysiological devices mimic the dynamic microenvironment of human skin and are gaining favor over static cell cultures for their superior ability to assess drug absorption and systemic toxicity. Significant investment is being directed toward expanding manufacturing capabilities for these technologies; for instance, CN Bio announced in April 2024 that it raised $21 million in Series B funding specifically to accelerate the commercial scaling of its PhysioMimix systems, underscoring the strong industry push toward physiologically relevant toxicological models.

Key Market Players

  • SGS S.A.
  • Covance, Inc
  • Bio-Rad Laboratories Inc.
  • Qiagen N.V.
  • GE Healthcare
  • Eurofins Scientific Inc
  • Merck KgaA
  • Thermo Fisher Scientific, Inc.
  • Charles River Laboratories International, Inc.
  • Catalent, Inc.

Report Scope

In this report, the Global Dermal Toxicity Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dermal Toxicity Testing Market, By Test Type

  • Skin Irritation Tests
  • Skin Sensitization Tests

Dermal Toxicity Testing Market, By Testing Method Type

  • In Vivo Testing (Animal-Based Tests)
  • In Vitro Testing (Cell-Based or Tissue-Based Tests)

Dermal Toxicity Testing Market, By End User

  • Pharmaceuticals industries
  • Cosmetics and personal care products industry
  • Chemical Industry
  • Other

Dermal Toxicity Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dermal Toxicity Testing Market.

Available Customizations:

Global Dermal Toxicity Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dermal Toxicity Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Skin Irritation Tests, Skin Sensitization Tests)
    • 5.2.2. By Testing Method Type (In Vivo Testing (Animal-Based Tests) and In Vitro Testing (Cell-Based or Tissue-Based Tests))
    • 5.2.3. By End User (Pharmaceuticals industries, Cosmetics and personal care products industry, Chemical Industry, Other)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Dermal Toxicity Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Testing Method Type
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Dermal Toxicity Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By Testing Method Type
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Dermal Toxicity Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By Testing Method Type
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Dermal Toxicity Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By Testing Method Type
        • 6.3.3.2.3. By End User

7. Europe Dermal Toxicity Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Testing Method Type
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Dermal Toxicity Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By Testing Method Type
        • 7.3.1.2.3. By End User
    • 7.3.2. France Dermal Toxicity Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By Testing Method Type
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Dermal Toxicity Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By Testing Method Type
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Dermal Toxicity Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By Testing Method Type
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Dermal Toxicity Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By Testing Method Type
        • 7.3.5.2.3. By End User

8. Asia Pacific Dermal Toxicity Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Testing Method Type
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Dermal Toxicity Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By Testing Method Type
        • 8.3.1.2.3. By End User
    • 8.3.2. India Dermal Toxicity Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By Testing Method Type
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Dermal Toxicity Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By Testing Method Type
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Dermal Toxicity Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By Testing Method Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Dermal Toxicity Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By Testing Method Type
        • 8.3.5.2.3. By End User

9. Middle East & Africa Dermal Toxicity Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Testing Method Type
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Dermal Toxicity Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By Testing Method Type
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Dermal Toxicity Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By Testing Method Type
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Dermal Toxicity Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By Testing Method Type
        • 9.3.3.2.3. By End User

10. South America Dermal Toxicity Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Testing Method Type
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Dermal Toxicity Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By Testing Method Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Dermal Toxicity Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By Testing Method Type
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Dermal Toxicity Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By Testing Method Type
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Dermal Toxicity Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. SGS S.A.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Covance, Inc
  • 15.3. Bio-Rad Laboratories Inc.
  • 15.4. Qiagen N.V.
  • 15.5. GE Healthcare
  • 15.6. Eurofins Scientific Inc
  • 15.7. Merck KgaA
  • 15.8. Thermo Fisher Scientific, Inc.
  • 15.9. Charles River Laboratories International, Inc.
  • 15.10. Catalent, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer